IP Library Granted Patent US 8,932,238
Granted Patent B2
US 8,932,238 · App. 12/794,669 · Granted Jan 13, 2015

Medical ultrasound device with liquid dispensing device coupled to a therapy head

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,932,238
App. No.
12/794,669
Granted
Jan 13, 2015
Kind
B2
Abstract

A medical ultrasound system. A base unit is included having system electronics, a user interface and ultrasound control electronics. An ultrasound therapy head is in electronic communication with the base unit. The therapy head includes a replaceable, sealed transducer cartridge with a coupling fluid therein. A cooling system is provided for cooling the coupling fluid. A plurality of guide indicators are positioned around the therapy head to align with crossed lines on a patient so as to properly align the therapy head prior to use. The therapy head can provide variable treatments to an area while the therapy head is in contact with a patient.

Claims (39)

1. A medical high intensity focused ultrasound system comprising:

a base unit including:

(a) a primary controller having a primary digital interface;

(b) a cooling liquid recirculation circuit; and

(c) a cable carrying an electrical transmission member, an information transmission member, and a plurality of cooling liquid conduits; and

a therapy head including:

(a) a body coupled to the cable;

(b) a secondary controller having a secondary digital interface, the secondary controller coupled to said primary controller by the electrical transmission member and the information transmission member; and

(c) a cartridge removably attached to the body, the cartridge including a sealed enclosure, an acoustic coupling liquid inside the sealed enclosure, and a high intensity focused ultrasound transducer in the acoustic coupling liquid inside the sealed enclosure, the cartridge further including a heat exchanger thermally coupled to draw heat from the acoustic coupling liquid without removing said acoustic coupling liquid from the sealed enclosure, the heat exchanger including a conduit disposed within the sealed enclosure and connected to inlet and outlet ports formed through the wall, the conduit of the heat exchanger coiled to surround a central space defined inside the sealed enclosure, and the inlet port of the conduit configured to receive a cooling liquid from the cooling liquid recirculation circuit via the cooling liquid conduits when the cartridge is attached to the body for circulation through the conduit to cool the acoustic coupling liquid while the acoustic coupling liquid remains isolated from the cooling liquid, and the high intensity ultrasound transducer coupled to the electrical transmission member when the cartridge is attached to the body,

wherein the high intensity ultrasound transducer is disposed in the central space, and the acoustic coupling liquid is separated by the heat exchanger from the cooling liquid supplied to the heat exchanger by the cooling liquid conduits.

2. The system of claim 1 , further comprising:

a liquid dispersion device on the therapy head, the liquid dispersion device configured to apply a liquid to the patient.

3. The system of claim 1 , wherein the high intensity ultrasound transducer comprises a short stack transducer assembly.

4. The system of claim 1 , wherein the primary digital interface and the secondary digital interface each further comprise a serialize and deserialize device.

5. The system of claim 1 , wherein the acoustic coupling liquid comprises degassed water and a salt.

6. A medical high intensity focused ultrasound system comprising:

a base unit including:

(a) a primary controller having a primary digital interface;

(b) a cooling liquid recirculation circuit; and

(c) a cable carrying an electrical transmission member, an information transmission member, and a plurality of cooling liquid conduits; and

a therapy head including:

(d) a body coupled to the cable;

(e) a secondary controller having a secondary digital interface, the secondary controller coupled to said primary controller by the electrical transmission member and the information transmission member; and

(f) a cartridge removably attached to the body, the cartridge including a sealed enclosure, an acoustic coupling liquid inside the sealed enclosure, and a high intensity focused ultrasound transducer in the acoustic coupling liquid inside the sealed enclosure, the cartridge further including a coiled heat exchanger coupled to the cooling liquid recirculation circuit via the cooling liquid conduits when the cartridge is attached to the body, and the transducer coupled to the electrical transmission member when the cartridge is attached to the body,

wherein the heat exchanger includes a thermoelectric device, the acoustic coupling liquid is separated by the heat exchanger from a cooling liquid supplied to the heat exchanger by the cooling liquid conduits, and at least a portion of the coiled heat exchanger is positioned inside the sealed enclosure.

7. The system of claim 6 , wherein the cable is flexible to allow substantially free manual manipulation of the therapy head.

8. The system of claim 7 , wherein there is no support arm between the base unit and the therapy head, and all mechanical, electrical, and fluid connections between the base unit and therapy head are provided by the cable.

9. The system of claim 6 , further comprising:

a liquid dispersion device on the therapy head, the liquid dispersion device configured to apply a liquid to the patient.

10. The system of claim 6 , wherein the liquid recirculation circuit further comprises a chiller.

11. The system of claim 6 , wherein the cable contains about twelve (12) to twenty four (24) coaxial cables.

12. The system of claim 6 , wherein the high intensity ultrasound transducer comprises a short stack transducer assembly.

13. The system of claim 6 , wherein the primary digital interface and the secondary digital interface each further comprise a serialize and deserialize device.

14. The system of claim 6 , wherein the acoustic coupling liquid comprises degassed water.

15. The system of claim 14 , wherein the degassed water is degassed to less than 12 ppm of dissolved oxygen.

16. The system of claim 14 , wherein the degassed water is degassed to less than or equal to 5 ppm of dissolved oxygen.

17. The system of claim 14 , wherein the acoustic coupling liquid further comprises a salt.

18. The system of claim 17 , wherein the salt is calcium chloride.

19. The system of claim 6 , wherein the sealed enclosure is permanently sealed.

Assignments (19)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
Reel/Frame 073654/0242 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
Reel/Frame 073637/0126 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
Reel/Frame 073654/0300 →
U.S. PATENT SECURITY AGREEMENT Recorded Jun 13, 2025
From: MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; BAUSCH HEALTH US, LLC (F/K/A VALEANT PHARMACEUTICALS NORTH AMERICA LLC); PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; BAUSCH HEALTH AMERICAS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 071564/0463 →
U.S. PATENT SECURITY AGREEMENT Recorded Jun 13, 2025
From: MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; BAUSCH HEALTH US, LLC (F/K/A VALEANT PHARMACEUTICALS NORTH AMERICA LLC); PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; BAUSCH HEALTH AMERICAS, INC.; SOLTA MEDICAL, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 071566/0200 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Oct 5, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061606/0468 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Oct 4, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061595/0066 →
SECURITY INTEREST Recorded Jun 13, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 060346/0705 →
SECURITY AGREEMENT Recorded Feb 10, 2022
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 059121/0001 →
SECURITY INTEREST Recorded Jun 8, 2021
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 056811/0814 →
MERGER Recorded May 13, 2021
From: AESTHERA; LIPOSONIX, INC.
To: SOLTA MEDICAL, INC.
Reel/Frame 056227/0174 →
SECURITY INTEREST Recorded Mar 11, 2019
From: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 048556/0758 →
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Jan 24, 2014
From: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
To: LIPOSONIX, INC.
Reel/Frame 032126/0370 →
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Jan 24, 2014
From: SILICON VALLEY BANK
To: LIPOSONIX, INC.
Reel/Frame 032126/0531 →
SHORT-FORM PATENT SECURITY AGREEMENT Recorded Nov 19, 2013
From: LIPOSONIX, INC.
To: CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; CAPITAL ROYALTY PARTNERS II L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
Reel/Frame 031674/0454 →
SECURITY INTEREST - MEZZANINE LOAN Recorded Apr 18, 2013
From: LIPOSONIX, INC.
To: SILICON VALLEY BANK
Reel/Frame 030249/0268 →
SECURITY AGREEMENT Recorded Apr 3, 2013
From: LIPOSONIX, INC.
To: SILICON VALLEY BANK
Reel/Frame 030147/0642 →
CHANGE OF NAME Recorded Jan 25, 2012
From: MEDICIS TECHNOLOGIES CORPORATION
To: LIPOSONIX, INC.
Reel/Frame 027595/0307 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2010
From: WING, GREGORY T.; KENNEY, MARTIN; LITTLE, BLAKE W.; FIX, RICHARD L.
To: MEDICIS TECHNOLOGIES CORPORATION
Reel/Frame 024533/0292 →